{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:05:22Z","timestamp":1777871122646,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00108-026-02102-8","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:34:10Z","timestamp":1774449250000},"page":"499-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prim\u00e4re Glomerulonephritiden","Primary glomerulonephritides"],"prefix":"10.1007","volume":"67","author":[{"given":"Elion","family":"Hoxha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"10032","key":"2102_CR1","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/S0140-6736(16)00272-5","volume":"387","author":"J Floege","year":"2016","unstructured":"Floege\u00a0J, Amann\u00a0K (2016) Primary glomerulonephritides. Lancet 387(10032):2036\u20132048","journal-title":"Lancet"},{"key":"2102_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1053\/j.ajkd.2011.05.033","volume":"58","author":"J Floege","year":"2011","unstructured":"Floege\u00a0J (2011) The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis 58:992\u20131004","journal-title":"Am J Kidney Dis"},{"key":"2102_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","volume":"104","author":"S Sethi","year":"2023","unstructured":"Sethi\u00a0S, Beck\u00a0LH Jr, Glassock\u00a0RJ et\u00a0al (2023) Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int 104:1092\u20131102","journal-title":"Kidney Int"},{"key":"2102_CR4","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","volume":"385","author":"P Ronco","year":"2015","unstructured":"Ronco\u00a0P, Debiec\u00a0H (2015) Pathophysiological advances in membranous nephropathy: time for a shift in patient`s care. Lancet 385:1983\u20131992","journal-title":"Lancet"},{"issue":"4S","key":"2102_CR5","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100(4S):S1\u2013S276","journal-title":"Kidney Int"},{"key":"2102_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan\u00a0A, Franssen\u00a0CF, de Vries\u00a0CS (2011) The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 26:414\u2013430","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2102_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung\u00a0CK, Alexander\u00a0S, Reich\u00a0HN et\u00a0al (2025) The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol 21(1):9\u201323","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2102_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou\u00a0E, Seikrit\u00a0C, Tang\u00a0SCW et\u00a0al (2023) IgA nephropathy. Nat Rev Dis Primers 9(1):67","journal-title":"Nat Rev Dis Primers"},{"key":"2102_CR9","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1681\/ASN.2012010063","volume":"23","author":"E Gutierrez","year":"2012","unstructured":"Gutierrez\u00a0E, Zamora\u00a0I, Ballarin\u00a0JA et\u00a0al (2012) Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J\u00a0Am Soc Nephrol 23:1753\u20131760","journal-title":"J Am Soc Nephrol"},{"issue":"10433","key":"2102_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","volume":"403","author":"K Wong","year":"2024","unstructured":"Wong\u00a0K, Pitcher\u00a0D, Braddon\u00a0F et\u00a0al (2024) Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet 403(10433):1279\u20131289","journal-title":"Lancet"},{"key":"2102_CR11","first-page":"1668","volume":"119","author":"H Suzuki","year":"2009","unstructured":"Suzuki\u00a0H, Fan\u00a0R, Zhang\u00a0Z et\u00a0al (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J\u00a0Clin Invest 119:1668\u20131677","journal-title":"J Clin Invest"},{"key":"2102_CR12","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen\u00a0T, Eitner\u00a0F, Fitzner\u00a0C et\u00a0al (2015) Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N\u00a0Engl J Med 373:2225\u20132236","journal-title":"N Engl J Med"},{"issue":"10417","key":"2102_CR13","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin\u00a0BH, Barratt\u00a0J, Heerspink\u00a0HJL et\u00a0al (2023) Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2\u2011year results from a randomised, active-controlled, phase 3 trial. Lancet 402(10417):2077\u20132090","journal-title":"Lancet"},{"issue":"10405","key":"2102_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette\u00a0R, Kristensen\u00a0J, Stone\u00a0A et\u00a0al (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2\u2011year results from a randomised phase 3 trial. Lancet 402(10405):859\u2013870","journal-title":"Lancet"},{"issue":"6","key":"2102_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic\u00a0V, Barratt\u00a0J, Rovin\u00a0B et\u00a0al (2025) Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N\u00a0Engl J Med 392(6):531\u2013543","journal-title":"N Engl J Med"},{"issue":"7","key":"2102_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","volume":"394","author":"V Perkovic","year":"2026","unstructured":"Perkovic\u00a0V, Trimarchi\u00a0H, Tesar\u00a0V et\u00a0al (2026) Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial. N\u00a0Engl J Med 394(7):635\u2013646","journal-title":"N Engl J Med"},{"issue":"7","key":"2102_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMoa2510198","volume":"394","author":"R Lafayette","year":"2026","unstructured":"Lafayette\u00a0R, Barbour\u00a0SJ, Brenner\u00a0RM et\u00a0al (2026) A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. N\u00a0Engl J Med 394(7):647\u2013657","journal-title":"N Engl J Med"},{"issue":"1","key":"2102_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco\u00a0P, Beck\u00a0L, Debiec\u00a0H et\u00a0al (2021) Membranous nephropathy. Nat Rev Dis Primers 7(1):69","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"2102_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","volume":"18","author":"E Hoxha","year":"2022","unstructured":"Hoxha\u00a0E, Reinhard\u00a0L, Stahl\u00a0RAK (2022) Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol 18(7):466\u2013478","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2102_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck\u00a0LH Jr, Bonegio\u00a0RG, Lambeau\u00a0G et\u00a0al (2009) M\u2011type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N\u00a0Engl J Med 361(1):11\u201321","journal-title":"N Engl J Med"},{"key":"2102_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ki.2012.209","volume":"82","author":"E Hoxha","year":"2012","unstructured":"Hoxha\u00a0E, Knei\u00dfler\u00a0U, Stege\u00a0G et\u00a0al (2012) Enhanced expression of the M\u2011type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82:797\u2013804","journal-title":"Kidney Int"},{"key":"2102_CR22","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco\u00a0N, Guti\u00e9rrez\u00a0E, Covars\u00ed\u00a0A et\u00a0al (2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J\u00a0Am Soc Nephrol 21:697\u2013704","journal-title":"J Am Soc Nephrol"},{"key":"2102_CR23","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2215\/CJN.03850414","volume":"9","author":"E Hoxha","year":"2014","unstructured":"Hoxha\u00a0E, Harendza\u00a0S, Pinnschmidt\u00a0H et\u00a0al (2014) M\u2011type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 9:1883\u20131890","journal-title":"Clin J Am Soc Nephrol"},{"key":"2102_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013040430","volume":"25","author":"E Hoxha","year":"2014","unstructured":"Hoxha\u00a0E, Thiele\u00a0I, Zahner\u00a0G et\u00a0al (2014) Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J\u00a0Am Soc Nephrol 25:1357\u20131366","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2102_CR25","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.ajt.2024.01.036","volume":"24","author":"F Hullekes","year":"2024","unstructured":"Hullekes\u00a0F, Uffing\u00a0A, Verhoeff\u00a0R et\u00a0al (2024) Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study. Am J Transplant 24(6):1016\u20131026","journal-title":"Am J Transplant"},{"issue":"10","key":"2102_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","volume":"18","author":"SJ Barbour","year":"2023","unstructured":"Barbour\u00a0SJ, Fervenza\u00a0FC, Induruwage\u00a0D et\u00a0al (2023) Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy. Clin J Am Soc Nephrol 18(10):1283\u20131293","journal-title":"Clin J Am Soc Nephrol"},{"key":"2102_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan\u00a0K, Debiec\u00a0H, Plaisier\u00a0E et\u00a0al (2017) Rituximab for Severe Membranous Nephropathy: A 6\u2011Month Trial with Extended Follow-Up. J\u00a0Am Soc Nephrol 28:348\u2013358","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2102_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza\u00a0FC, Appel\u00a0GB, Barbour\u00a0SJ et\u00a0al (2019) Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N\u00a0Engl J Med 381(1):36\u201346","journal-title":"N Engl J Med"},{"key":"2102_CR29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari\u00a0F, Delbarba\u00a0E, Santoro\u00a0D et\u00a0al (2021) Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. J\u00a0Am Soc Nephrol 32:972\u2013982","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2102_CR30","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/ASN.2016091022","volume":"28","author":"JAJG van den Brand","year":"2017","unstructured":"van den Brand\u00a0JAJG, Ruggenenti\u00a0P, Chianca\u00a0A et\u00a0al (2017) Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J\u00a0Am Soc Nephrol 28(9):2729\u20132737","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"2102_CR31","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas\u00a0NM, Beck\u00a0LH Jr, Meyer-Schwesinger\u00a0C et\u00a0al (2014) Thrombospondin type\u20111 domain-containing 7A in idiopathic membranous nephropathy. N\u00a0Engl J Med 371(24):2277\u20132287","journal-title":"N Engl J Med"},{"key":"2102_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","volume":"97","author":"S Sethi","year":"2020","unstructured":"Sethi\u00a0S, Debiec\u00a0H, Madden\u00a0B et\u00a0al (2020) Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 97:163\u2013174","journal-title":"Kidney Int"},{"issue":"20","key":"2102_CR33","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMc1511702","volume":"374","author":"E Hoxha","year":"2016","unstructured":"Hoxha\u00a0E, Wiech\u00a0T, Stahl\u00a0PR et\u00a0al (2016) A Mechanism for Cancer-Associated Membranous Nephropathy. N\u00a0Engl J Med 374(20):1995\u20131996","journal-title":"N Engl J Med"},{"key":"2102_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ckj\/sfac237","volume":"16","author":"S Sethi","year":"2022","unstructured":"Sethi\u00a0S (2022) The Many Faces of NELL1 MN. Clin Kidney\u00a0J 16:442\u2013446","journal-title":"Clin Kidney J"},{"key":"2102_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1053\/j.ajkd.2011.07.024","volume":"59","author":"SS Chugh","year":"2012","unstructured":"Chugh\u00a0SS, Clement\u00a0LC, Mace\u00a0C (2012) New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis 59:284\u2013292","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2102_CR36","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2215\/CJN.07180622","volume":"17","author":"RE Campbell","year":"2022","unstructured":"Campbell\u00a0RE, Thurman\u00a0JM (2022) The Immune System and Idiopathic Nephrotic Syndrome. Clin J Am Soc Nephrol 17(12):1823\u20131834","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2102_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts\u00a0AJB, Keller\u00a0KH, Lerner\u00a0G et\u00a0al (2022) Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. J\u00a0Am Soc Nephrol 33(1):238\u2013252","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2102_CR38","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.kint.2024.09.006","volume":"106","author":"V Raglianti","year":"2024","unstructured":"Raglianti\u00a0V, Angelotti\u00a0ML, Cirillo\u00a0L et\u00a0al (2024) Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants. Kidney Int 106(6):1124\u20131134","journal-title":"Kidney Int"},{"issue":"Suppl 6","key":"2102_CR39","first-page":"vi52","volume":"18","author":"RJ Glassock","year":"2003","unstructured":"Glassock\u00a0RJ (2003) Secondary minimal change disease. Nephrol Dial Transplant 18(Suppl 6):vi52\u2013vi58","journal-title":"Nephrol Dial Transplant"},{"key":"2102_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1681\/ASN.2012070734","volume":"24","author":"J Hogan","year":"2013","unstructured":"Hogan\u00a0J, Radhakrishnan\u00a0J (2013) The treatment of minimal change disease in adults. J\u00a0Am Soc Nephrol 24:702\u2013711","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2102_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2215\/CJN.06180519","volume":"15","author":"NR Medjeral-Thomas","year":"2020","unstructured":"Medjeral-Thomas\u00a0NR, Lawrence\u00a0C, Condon\u00a0M et\u00a0al (2020) Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 15(2):209\u2013218","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2102_CR42","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/nep.13554","volume":"24","author":"R Ramachandran","year":"2019","unstructured":"Ramachandran\u00a0R, Bharati\u00a0J, Rao\u00a0I et\u00a0al (2019) Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. Nephrology 24(12):1241\u20131247","journal-title":"Nephrology"},{"key":"2102_CR43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","volume":"14","author":"C Xue","year":"2020","unstructured":"Xue\u00a0C, Yang\u00a0B, Xu\u00a0J et\u00a0al (2020) Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clin Kidney\u00a0J 14:1042\u20131054","journal-title":"Clin Kidney J"},{"issue":"2","key":"2102_CR44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli\u00a0M, Massella\u00a0L, Ruggiero\u00a0B et\u00a0al (2017) Minimal change disease. Clin J Am Soc Nephrol 12(2):332\u2013345","journal-title":"Clin J Am Soc Nephrol"},{"key":"2102_CR45","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1681\/ASN.2014050489","volume":"26","author":"CE Sadowski","year":"2015","unstructured":"Sadowski\u00a0CE, Lovric\u00a0S, Ashraf\u00a0S et\u00a0al (2015) A single-gene cause in 29.5\u202f% of cases of steroid-resistant nephrotic syndrome. J\u00a0Am Soc Nephrol 26:1279\u20131289","journal-title":"J Am Soc Nephrol"},{"key":"2102_CR46","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1001\/jama.1983.03340210033020","volume":"250","author":"EE Cunningham","year":"1983","unstructured":"Cunningham\u00a0EE, Zielezny\u00a0MA, Venuto\u00a0RC (1983) Heroin-associated nephropathy. A nationwide problem. JAMA 250:2935\u20132936","journal-title":"JAMA"},{"key":"2102_CR47","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/ndt\/16.9.1790","volume":"16","author":"M Praga","year":"2001","unstructured":"Praga\u00a0M, Hern\u00e1ndez\u00a0E, Morales\u00a0E et\u00a0al (2001) Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 16:1790\u20131798","journal-title":"Nephrol Dial Transplant"},{"key":"2102_CR48","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJM198403153101101","volume":"310","author":"TK Rao","year":"1984","unstructured":"Rao\u00a0TK, Filippone\u00a0EJ, Nicastri\u00a0AD et\u00a0al (1984) Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N\u00a0Engl J Med 310:669\u2013673","journal-title":"N Engl J Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02102-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:02:05Z","timestamp":1777568525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02102-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2102"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02102-8","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Hoxha gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}